Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-NK224
- Development stage
- Unknown
- Lead developer
- First Affiliated Hospital of Xiamen University
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Peptides
- Administration
- Intravenous
01
Overview
68Ga-NK224 is an investigational, peptide-based PET diagnostic radiotracer targeting human programmed cell death ligand 1 (PD-L1). It consists of a cyclic peptide (NK224) derived from DK221, conjugated to a NOTA chelator, which allows for radiolabeling with gallium-68 (or alternatively fluorine-18). Developed by academic investigators at the First Affiliated Hospital of Xiamen University, 68Ga-NK224 is designed to noninvasively map and quantify whole-body PD-L1 expression, assess intratumoral and intertumoral heterogeneity, and monitor PD-L1 target occupancy during anti-PD-L1 immunotherapy. In clinical studies of patients with non-small cell lung cancer (NSCLC), 68Ga-NK224 PET/CT was well tolerated and demonstrated a strong correlation between tumor tracer uptake and PD-L1 expression levels determined by immunohistochemistry, offering a promising noninvasive alternative to single-site tissue biopsies for patient stratification and treatment monitoring.
- Other names
- 68Ga-NOTA-NK224Ga-68 NK224Ga68 NK224Ga 68 NK224gallium Ga 68 NK224gallium-68 NK224gallium68 NK224gallium 68 NK224
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on 68Ga-NK224.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 68Ga-NK224.